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Cyclin D1 is an oncogene frequently overexpressed in human cancers that has a dual
function as cell cycle and transcriptional regulator, although the latter is widely unexplored.
Here, we investigated the transcriptional role of cyclin D1 in lymphoid tumor cells with cyclin
D1 oncogenic overexpression. Cyclin D1 showed widespread binding to the promoters of
most actively transcribed genes, and the promoter occupancy positively correlated with the
transcriptional output of targeted genes. Despite this association, the overexpression of
cyclin D1 in lymphoid cells led to a global transcriptional downmodulation that was
proportional to cyclin D1 levels. This cyclin D1–dependent global transcriptional
downregulation was associated with a reduced nascent transcription and an accumulation
of promoter-proximal paused RNA polymerase II (Pol II) that colocalized with cyclin D1.
Concordantly, cyclin D1 overexpression promoted an increase in the Poll II pausing index.
This transcriptional impairment seems to be mediated by the interaction of cyclin D1 with
the transcription machinery. In addition, cyclin D1 overexpression sensitized cells to
transcription inhibitors, revealing a synthetic lethality interaction that was also observed in
primary mantle cell lymphoma cases. This finding of global transcriptional dysregulation
expands the known functions of oncogenic cyclin D1 and suggests the therapeutic potential
of targeting the transcriptional machinery in cyclin D1–overexpressing tumors.
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Introduction
Cyclin D1 plays a central role in cell cycle regulation, and it is fre-
quently upregulated in cancer by different genomic alterations, 
including amplifications in breast and respiratory tract tumors 
(1–4) and chromosomal translocations in mantle cell lymphoma 
(MCL) and multiple myeloma (MM) (5, 6). Moreover, point muta-
tions disrupting the nuclear export process have been described 
in esophageal and endometrial carcinomas (7, 8). All these genet-
ic alterations lead to an oncogenic overexpression of cyclin D1. 
Remarkably, CCND1, which encodes cyclin D1, was the most sig-
nificantly amplified gene among the 12 tumor types recently ana-
lyzed in the Cancer Genome Atlas Pan-Cancer analysis project (9).
The classical tumorigenesis model considers that cyclin D1 
mediates its oncogenic effect through its binding to CDK4, fol-
lowed by pRB phosphorylation, E2F release, and subsequent pro-
motion of the G1/S phase transition (10). However, during the last 
decade, a growing body of evidence has established that cyclin D1 
has additional roles besides its canonical cell cycle function (11–
13). The description of cyclin D1 interactions with transcription 
factors and with chromatin-remodeling and histone-modifying 
enzymes has revealed a potential role of cyclin D1 as a transcrip-
tional regulator in different cell models (14–17). However, whether 
oncogenic overexpression of cyclin D1 is responsible for transcrip-
tional dysregulation in cancer cells remains unknown.
MCL is an aggressive lymphoid neoplasm that represents the 
paradigm of a neoplasia with cyclin D1–dependent oncogenesis. 
The t(11;14) (q13;q32) translocation that leads to constitutive overex-
pression of cyclin D1 is the initial oncogenic event in this lymphoma 
(18). The relevance of cyclin D1 dysregulation in MCL pathogenesis 
is stressed by the recognition that MCL cells adopt different mech-
anisms to increase the levels of cyclin D1, such as amplification of 
the translocated allele or secondary rearrangements and muta-
tions involving the 3′ untranslated region that generate more sta-
ble CCND1 transcripts (19–21). The expression of these abnormal 
transcripts correlates with the presence of higher protein levels and 
increased aggressiveness of the tumors (22). Recently, mutations at 
the cyclin D1 N-terminal region have been identified in MCL that 
also lead to increased stability of the protein (23, 24).
In this study, we have investigated the role of cyclin D1 over-
expression as a transcriptional regulator in malignant lymphoid 
cells. Integration of ChIP sequencing (ChIP-Seq) data on cyclin 
D1 with data on histone modifications and the transcriptional 
output of MCL cell lines revealed that cyclin D1 binds to the pro-
moters of most actively transcribed genes, and its overexpression 
led to global downmodulation of the transcriptome program. This 
effect was associated with an accumulation of promoter-proximal 
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not present at promoters lacking active histone marks and DNase 
I hypersensitive sites (Figure 2A). Although cyclin D1 localized 
preferentially to active promoters, characterized by the presence 
of H3K27ac and H3K4me3 histone modifications, a fraction of 
cyclin D1 peaks also occurred at active enhancers, characterized 
by H3K27ac and H3K4me1 histone modifications (Figure 2C). The 
cyclin D1 binding density at active promoters was significantly 
higher than that observed in enhancers (Figure 2D; P < 2.2 × 10–16). 
Taken together, these results indicate that cyclin D1 binds to 
regions of open chromatin enriched in active histone marks, which 
include promoters and enhancers.
Cyclin D1 occupies promoters of highly expressed genes. To study 
the relationship between the binding of cyclin D1 to promoters 
and the transcriptional output, we performed RNA sequencing 
(RNA-Seq) of the MCL cell lines. Interestingly, when all coding 
genes were stratified according to mRNA expression levels, the 
groups with higher gene expression values displayed larger frac-
tions of cyclin D1–bound genes (Figure 3A). Furthermore, cyclin 
D1 promoter occupancy showed a strong positive correlation with 
gene expression levels (ρ = 0.98, P < 2.2 × 10–16) (Figure 3B), and 
the average binding density around the TSS was proportional to 
the transcription output of the genes (Figure 3C and Supplemen-
tal Figure 2A). These results were consistent with the high degree 
of overlap observed between cyclin D1–binding sites and active 
chromatin marks. Moreover, when we combined the expression 
of primary MCL cases (n = 122) with the cyclin D1 peak density 
found in MCL cell lines, we observed a highly significant correla-
tion between cyclin D1 promoter binding density in MCL cell lines 
and expression levels of the genes in primary MCL cases (Figure 
3D, ρ = 0.97, P < 2.2 × 10–16). This result shows that genes actively 
transcribed in MCL cell lines with cyclin D1 promoter binding are 
also highly expressed in primary MCL cases. Together, our results 
demonstrate that cyclin D1 binding occurs predominantly around 
the TSS of abundantly transcribed genes, suggesting that cyclin D1 
might regulate transcription in MCL cells.
Genome-wide recruitment of exogenous cyclin D1 to active gene 
promoters. We wanted to investigate whether exogenous cyclin D1 
would be recruited to promoters and preferentially to the actively 
transcribed genes, in a manner similar to endogenous cyclin D1. 
To that end, we transduced a cyclin D1–negative lymphoblastoid 
leukemic cell line (JVM13) to constitutively express a nuclear 
active form of cyclin D1 carrying the T286A mutation (JVM13- 
cD1T286A). This mutation prevents physiological nuclear export and 
subsequent degradation of the cyclin, allowing cyclin D1 protein 
to reach levels more similar to those observed in MCL cell lines 
(Supplemental Figure 2B). The cyclin D1 DNA binding profile 
observed in JVM13-cD1T286A cells was comparable to the pattern 
identified in the MCL cell lines (Figure 3E), despite the fact that a 
lower number of cyclin D1 peaks was observed. The reduced num-
ber of peaks could be due to the lower amount of cyclin D1 pro-
tein constitutively expressed by JVM13-cD1T286A compared with 
the MCL cell lines. In fact, the correlation observed between the 
number of identified peaks and the amount of cyclin D1 protein in 
MCL cell lines was strengthened when JVM13-cD1T286A data were 
included (r = 0.98; Supplemental Figure 2C). This result suggests 
that the degree of cyclin D1 chromatin binding is proportional to 
the amount of cyclin D1 protein.
paused RNA polymerase II (Pol II) that overlapped with cyclin 
D1–bound regions. In concordance with the presence of higher lev-
els of paused Pol II, the overexpression of cyclin D1 promoted an 
increase in the Pol II pausing index. This transcriptional dysregula-
tion seems to be mediated by the physical interaction of cyclin with 
the transcription machinery. Finally, cyclin D1–overexpressing 
cells showed greater sensitivity to transcription inhibitors, a phe-
notype also observed in primary MCL cases, suggesting a synthetic 
lethality interaction that may open new therapeutic opportunities 
in cyclin D1–overexpressing tumors.
Results
Cyclin D1 shows extensive genome-wide chromatin binding in MCL 
cells. In order to characterize the genome-wide chromatin binding 
pattern of cyclin D1, we performed ChIP-Seq of endogenous cyclin 
D1 in 4 MCL cell lines (Z-138, GRANTA-519, Jeko-1, and UPN-1). 
All these cell lines carry the t(11;14) translocation and display 
variable levels of cyclin D1 protein overexpression (Supplemental 
Figure 1A; supplemental material available online with this arti-
cle; https://doi.org/10.1172/JCI96520DS1). Of note, we found a 
high number of cyclin D1 DNA-binding regions, with 19,860 peaks 
common to all 4 MCL cell lines (Figure 1A). Interestingly, the num-
ber of identified peaks displayed a strong positive correlation with 
the amount of cyclin D1 protein (r = 0.87) (Supplemental Figure 
1B). The annotation of the peaks as promoter, gene body (exon 
or intron), or intergenic revealed enrichment in promoters (Sup-
plemental Table 1). Peaks at promoters showed higher tag densi-
ty, and, concordantly, when a tag density filter was applied, more 
than 50% of the peaks were classified as promoters (Figure 1B and 
Supplemental Table 2). In total, an average of 11,583 coding genes 
displayed cyclin D1 binding to their proximal promoters, and more 
than 74% of them were common among the 4 cell lines (n = 8,638) 
(Figure 1C). The actual distribution of cyclin D1–binding sites 
showed that these interactions tend to occur close to and centered 
around the transcription start sites (TSS) of the genes (Figure 1D). 
Functional pathway analysis of genes showing cyclin D1 occupancy 
at promoters revealed that these genes were related to processes 
such as translation, RNA processing, cell cycle, and DNA damage 
and repair, among others (Figure 1E and Supplemental Table 3).
To validate the cyclin D1 promoter binding, we performed 
ChIP–quantitative PCR (ChIP-qPCR) of 8 genes with cyclin D1 
peaks close to their TSS (Figure 1F and Supplemental Figure 1C). 
All the tested genes showed marked cyclin D1 binding enrichment 
when compared with a negative region (Figure 1G). The interaction 
of cyclin D1 with promoters is consistent with a transcriptional func-
tion of the cyclin in MCL cells, and the extensive binding observed 
across the genome is compatible with a global transcriptional role.
Cyclin D1 binds to open chromatin regions enriched in active his-
tone marks. To further characterize the global binding of cyclin D1 
and its potential transcriptional role, we investigated the features 
of the cyclin D1–associated chromatin. To do so, we compared the 
cyclin D1 binding pattern to the profiles of several histone marks 
and DNase I hypersensitive sites obtained for the Z-138 cell line 
in the context of the Blueprint Epigenome consortium (25). We 
observed that promoters occupied by cyclin D1 were enriched 
in active histone marks (H3K4me3 and H3K27ac) and DNase I 
hypersensitive sites (Figure 2, A and B). Conversely, cyclin D1 was 
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the transcription levels of the genes, similar to what was observed 
for endogenous cyclin D1 (Supplemental Figure 2D). In addition, 
the combination of the basal gene expression profile of JVM13 
cells with cyclin D1 chromatin binding showed that genes bound 
by exogenous cyclin D1 were already actively transcribed prior 
to the presence of cyclin D1, and the genome-wide recruitment 
around the TSS correlated with the previous mRNA levels of the 
To determine the possible association between the chroma-
tin binding of exogenous cyclin D1 and the transcriptome output, 
we performed RNA-Seq of JVM13-cD1T286A cells. The integration 
of ChIP-Seq and RNA-Seq data sets showed a strong positive cor-
relation between gene expression levels and exogenous cyclin D1 
promoter density (ρ = 0.97, P < 2.2 × 10–16; Figure 3F). Moreover, 
the average binding density around the TSS was proportional to 
Figure 1. Cyclin D1 binds genome-wide in MCL cell lines. (A) Venn diagram representing cyclin D1 ChIP-Seq peaks in 4 MCL cell lines. (B) Distribution of 
cyclin D1–interacting regions over specific genomic regions in MCL cell lines. Box plots showing cyclin D1 tag density of the different genomic regions and 
pie charts displaying the genomic distribution of genomic intervals, with a number of tags higher than the mean. The distribution across the human 
genome is represented as a control. (C) Venn diagram representing cyclin D1–targeted genes identified by ChIP-Seq in MCL cell lines. Genes were consid-
ered targets when they displayed cyclin D1–binding sites located within 1 kb upstream of their TSS. (D) Average signal profile of cyclin D1 around the TSS 
(±3 kb) in MCL cell lines. (E) Top hits of the functional annotation clustering analysis of common cyclin D1 target genes among the 4 MCL cell lines. Only 
the genes with the most significant peaks in their promoters (–log P > 350) were considered for the analysis. (F) Genome browser view of the ChIP-Seq 
tag density plots of 4 representative cyclin D1 target genes. (G) ChIP-qPCR validation of 8 selected cyclin D1 target genes in GRANTA-519. The fold change 
enrichments relative to a negative region are presented (mean ± SEM) (n = 2).
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of MYC was associated with an increase in total RNA and mRNA, 
which led to the identification of MYC as a global transcription-
al amplifier (26–28). To analyze whether the genome-wide chro-
matin binding pattern of cyclin D1 is related to a potential role 
of the cyclin as a global transcriptional regulator, we explored 
the relationship between cyclin D1 expression and total cellular 
RNA content. We overexpressed in JVM13 cells either the highly 
stable nuclear form of cyclin D1 (JVM13-D1T286A) or the WT form 
of the protein (JVM13-D1). As expected, inducible JVM13-D1T286A 
cells showed higher cyclin D1 protein levels than JVM13-D1 cells 
(Figure 4A). Following cyclin D1 induction, we performed spectro-
photometric analysis of the absolute levels of total RNA obtained 
from a fixed number of cells (Figure 4B). Unexpectedly, cyclin 
D1–overexpressing cells showed significantly lower amounts of 
total RNA per cell than JVM13 control cells (Figure 4B). In order 
to exclude that the reduction in the amount of total RNA could be 
related to the cell cycle distribution of the cells, we measured the 
amount of total RNA by flow cytometry using pyronin Y (RNA) 
and Hoechst (DNA) costaining. This approach confirmed that the 
significant decrease in the absolute levels of RNA content due to 
cyclin D1 overexpression was independent of the cell cycle phase, 
bound genes (Supplemental Figure 2E). Together, these results 
suggest that cyclin D1 may be recruited to promoters that are pre-
configured in an active state, and the extent of recruitment would 
be dependent on the transcriptional levels of the targeted genes.
Cyclin D1 overexpression leads to a global reduction in RNA syn-
thesis in lymphoid cells. The cyclin D1 chromatin binding pattern 
identified in MCL cell lines and JVM13 cells overexpressing cyclin 
D1 evidenced important similarities to that recently reported 
for MYC (26–28). Both proteins display extensive genome-wide 
binding to open chromatin, preferentially centered around the 
TSS of highly expressed genes, together with a unimodal distri-
bution in a peak-density histogram (Supplemental Figure 3A and 
refs. 26–28). Indeed, when we compared the chromatin binding 
of cyclin D1 with the MYC peaks previously described in a nor-
mal B cell (GM12878), we observed that more than 23% of pro-
moters bound by cyclin D1 also had been reported to be occupied 
by MYC in normal B cells (29). Moreover, the 2 proteins showed 
a similar chromatin binding profile (Supplemental Figure 3B). In 
addition, the cyclin D1 peaks that colocalized with MYC showed 
a significantly higher tag density (P < 2.2 × 10–16; Supplemental 
Figure 3C). Interestingly, the particular chromatin binding pattern 
Figure 2. Cyclin D1 occupancy correlates with active promoter marks and open chromatin conformation. (A) Heatmap showing the ChIP-Seq tag density 
of cyclin D1, H3K27ac, H3K4me3, H3K4me1, and DNase I cutting sites around all genomic TSS in Z-138 cells. Each row represents a gene centered on the 
TSS (±5 kb). Promoters are sorted by cyclin D1 number of tags. Cyclin D1–bound (top) and –unbound (bottom) genes are shown. (B) Pie chart representing 
common regions bound by cyclin D1, H3K27ac, and H3K4me3 marks. Only cyclin D1 peaks at promoters (–5 kb TSS) in Z-138 cells are shown. (C) Cyclin D1 
occupancy in active promoters and enhancers. Percentage of active promoters (H3K4me3+) and enhancers (H3K4me1+, H3K4me3–) colocalizing with cyclin 
D1 in active regions (defined by H3K27ac presence) are shown. (D) Box plot showing cyclin D1 number of tags in active promoters and active enhancers. The 
number of all cyclin D1 peaks is represented as control. ***P < 2.2 × 10–16, Student’s t test, Holm-Bonferroni correction.
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cells displayed a significant diminution in the amount of total RNA 
per cell when compared with JVM2 control cells. The reduction 
was not observed in JVM2-D1 cells, which displayed low cyclin D1 
levels (Supplemental Figure 4, B, C, and E).
To further confirm these results, we knocked down cyclin D1 in 
the MCL cell line GRANTA-519 using 2 independent shRNA con-
structs (Figure 4D). In agreement with the overexpression experi-
ments, cyclin D1 depletion led to a significant increase in the total 
since it was observed in both G1 and G2/M cells (Figure 4C and 
Supplemental Figure 4A). Remarkably, the reduction was greater 
in JVM13-D1T286A cells, which express higher levels of cyclin D1 
protein. In addition, we transduced the lymphoblastoid JVM2 cell 
line, which expresses low levels of endogenous cyclin D1 despite 
harboring the t(11;14) translocation, with the stable nuclear 
(JVM2-D1T286A) or the WT form of cyclin D1 (JVM2-D1) (Supple-
mental Figure 4E). RNA quantification showed that JVM2-D1T286A 
Figure 3. Cyclin D1 binding correlates with gene expression levels. (A) Distribution of genes showing cyclin D1 peaks within their promoters (5 kb 
upstream of the TSS) according to their respective gene expression levels. All genes were sorted into 50 equal bins based on their expression levels. 
Results are shown as mean ± SEM of all 4 MCL cell lines. (B) Linear correlation between cyclin D1 binding and transcription. Genes were sorted as in A. The 
average of cyclin D1 ChIP-Seq normalized tag densities at promoters and the RPKM-normalized expression levels are shown for each bin. Spearman’s cor-
relation, ρ = 0.98, P < 2.2 × 10–16. (C) Profile of cyclin D1 occupancy around the TSS in Z-138 cells. Genes were divided into 10 groups based on their expres-
sion levels (from higher to lower expression). The distribution of the cyclin D1 ChIP-Seq tag density average around the TSS (±1 kb) is displayed for each 
group. (D) Linear correlation between cyclin D1 binding in MCL cell lines and gene expression in MCL primary samples (n = 122). Genes were sorted into 50 
equal bins based on their expression in MCL samples. For each bin, the cyclin D1 ChIP-Seq tag density average in the MCL cell lines and the gene expression 
mean in primary samples are shown. Spearman’s correlation, ρ = 0.97, P < 2.2 × 10–16. (E) Heatmap showing the cyclin D1 ChIP-Seq tag density within gene 
promoters of JVM13-cD1T286A and MCL cell lines. Each row represents a gene centered on the TSS (±5 kb). Promoters are sorted by the number of cyclin D1 
tags in Z-138 cells. (F) Linear correlation between cyclin D1 binding and gene expression in JVM13-cD1T286A cells. Genes were sorted into 50 equal bins as in B. 
Spearman’s correlation, ρ = 0.97, P < 2.2 × 10–16.
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Figure 4. Cyclin D1 overexpression results in a reduction in the total RNA content in malignant lymphoid cells. (A) Cyclin D1 protein in JVM13-con-
trol (JVM13-ctrl), JVM13-D1, and JVM13-D1T286A cells. α-Tubulin was used as loading control. (B) Total RNA content extracted from 106 cells. Results are 
shown relative to the control (mean ± SEM, n = 9). *P < 0.05, Student’s t test. (C) RNA quantification by pyronin Y staining in JVM13 inducible cell lines. 
Only cells in G1 phase were analyzed. Left panel: FACS profile of a representative experiment. Right panel: Bar graph displaying the pyronin Y mean 
signal. Results are shown relative to the control (mean ± SEM, n = 3). *P < 0.05, **P < 0.01, Student’s t test. (D) Cyclin D1 expression in control (shCtrl) 
and cyclin D1–depleted (shCycD1 #1 and #2) GRANTA-519 cells. α-Tubulin was used as loading control. (E) Total RNA content in cyclin D1–depleted 
GRANTA-519 cells as in A. Results are shown relative to the control (mean ± SEM, n = 8), **P < 0.01, ***P < 0.001, Student’s t test. (F) RNA quanti-
fication by pyronin Y staining in control and cyclin D1–depleted GRANTA-519 cells as in B. Left and right panels as in C. Results are shown relative to 
the control (mean ± SEM, n = 4), **P < 0.01, ***P < 0.001, Student’s t test. (G) Correlation between cyclin D1 protein levels and pyronin Y staining in 
MCL cell lines and cell models. Mean ± SEM, n = 4; P = 4.77 × 10–4, mixed-effects models. (H) Pyronin Y intensity of 7 MM cell lines. The cell lines are 
represented by squares shaded according cyclin D1 levels. (I and J) Quantification of nuclear EU intensity after 24 hours of cyclin D1 induction in JVM13 
cell models (n = 2) (I) or following cyclin D1 silencing in the GRANTA-519 cell line (n = 2) (J). **P < 0.01, ***P < 0.001, Student’s t test. Holm-Bonferroni 
correction for multiple comparisons was applied to B, C, E, and F.
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RNA content per cell (Figure 4, E and F). Once again, the cyclin 
D1 effect was dose related, since the cells with the greatest knock-
down efficiency showed the highest increase in RNA amount, and 
it was cell cycle independent (Supplemental Figure 4D). Then, we 
investigated whether the different MCL cell lines showed the pre-
dicted association between cyclin D1 levels and the amount of total 
RNA. The analysis identified a highly significant inverse correla-
tion between cyclin D1 protein levels and total RNA amount mea-
sured by flow cytometry (Figure 4G and Supplemental Figure 2E). 
This association remained significant when exogenous cyclin D1– 
overexpressing and cyclin D1–depleted cells were included (P < 
4.77 × 10–4; Figure 4G and Supplemental Figure 4E). We next inves-
tigated whether this effect was also present in MM, a lymphoid neo-
plasm showing cyclin D1 upregulation due to the t(11;14) transloca-
tion or gene amplification in a substantial fraction of the cases. The 
analysis of MM cell lines with or without the t(11;14) translocation 
confirmed in a different cancer cell model the negative correlation 
between cyclin D1 protein levels and total RNA cell content (Fig-
ure 4H and Supplemental Figure 4F). Finally, RNA quantification 
in primary MCL cases (n = 11) also evidenced a negative correla-
tion between the levels of cyclin D1 and the amount of total RNA, 
although it did not reach statistical significance (r = –0.4, P = 0.2; 
Supplemental Figure 4G and Supplemental Figure 7C).
In order to test whether this reduction in steady-state RNA 
levels reflects a decrease in RNA synthesis, we performed nascent 
RNA-labeling experiments. We measured the incorporation of 
5-ethylnyl-uridine (EU) in JVM13, JVM13-D1, and JVM13-D1T286A 
cells to quantify the rate of nascent transcription at the single-cell 
level. Interestingly, cyclin D1 overexpression led to a significant 
reduction in transcription (Figure 4I and Supplemental Figure 
5A). Accordingly, cyclin D1 depletion in the GRANTA-519 cell 
line revealed a significant increase in RNA synthesis (Figure 4J 
and Supplemental Figure 5B). Together, these results suggest 
that cyclin D1 oncogenic overexpression induces a reduction in 
steady-state RNA levels in a dose-dependent manner by decreas-
ing total transcription.
Cyclin D1 produces a global downmodulation of mRNAs in lym-
phoid cells. We investigated whether the reduced transcription 
promoted by cyclin D1 overexpression also determines a global 
mRNA downregulation. The decrease in the quantity of total RNA 
per cell following cyclin D1 overexpression compromises the use 
of genome-wide approaches such as microarrays or RNA-Seq to 
explore the presence of a global mRNA downmodulation, since 
these strategies usually compare the same amount of RNA between 
conditions (30). To overcome this limitation, we took advantage 
of NanoString’s nCounter technology, which is able to perform a 
Figure 5. Cyclin D1 overexpression produces a global downmodulation of mRNAs in lymphoid cells. (A) Box plot displaying nCounter-based gene expres-
sion data of a 48-gene panel analyzed in JVM13-Ctrl and JVM13-cD1T286A cells. Cell extracts from 3 different amounts of cells, counted by cell cytometry, are 
represented on the x axis. The nCounter counts of expressed transcripts (counts >30) are shown in log2 scale on the y axis (n = 2). ***P < 2 × 10
–16, Student’s 
paired t test. (B) Box plot displaying the mean gene expression level in the JVM13-D1T286A line of genes expressed in the cancer panel according to cyclin 
D1 tag density at promoters (–5 kb, TSS) in JVM13-cD1T286A cells distributed in 4 quartiles (Q1–Q4). Cell extracts from 4 × 104 cells were analyzed (n = 2). P = 
1.7 × 10–6, ANOVA. (C) Box plot displaying the mean gene expression level in the JVM13-Ctrl and JVM13-D1T286A inducible cell lines of genes expressed in the 
cancer panel. Cell extracts from 4 × 104 cells were analyzed (n = 2). ***P < 2 × 10–16, Student’s paired t test. (D) Bar plots displaying the gene expression 
ratio between JVM13-Ctrl and JVM13-D1T286A inducible cell lines. Genes, both upregulated (gray) and downregulated (red), are sorted from the highest to the 
lowest expression ratio over JVM13-Ctrl.
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levels, we analyzed the expression of a commercial predesigned 
panel of 236 cancer-related genes in the JVM13-D1T286A cell line 
following cyclin D1 induction. Control cells expressed 154 of the 
236 genes. Observing results consistent with the RNA-Seq results, 
we found an association between the cyclin D1 tag density and 
the gene expression levels in JVM13-D1T286A cells (Figure 5B, P 
= 1.7 × 10–6). Remarkably, the average expression of these genes 
was significantly lower in JVM13-D1T286A cells (Figure 5C). 94% 
(n = 145) of the genes expressed in control cells were expressed at 
lower mRNA levels in JVM13-D1T286A cells (Figure 5D). To explore 
whether this mRNA downmodulation would include tumor sup-
pressor genes (TSGs), we compiled a set of 583 genes defined as 
TSGs (32). We found that 30 of 33 (91%) expressed TSGs were 
downregulated in JVM13-D1T286A cells. Interestingly, the TSGs 
direct digital quantification of cell extracts. We hybridized a com-
mercial predefined panel containing 48 genes derived from the 
MicroArray Quality Control Study (MAQC) (31) with cell extracts 
from 3 different amounts of cells corresponding to the cyclin D1 
overexpression model (JVM13 and JVM13-cD1T286A). The high cor-
relation observed between mRNA counts and the number of cells 
confirmed the suitability of this approach to test the global effect 
of cyclin D1 (JVM13-control, r = 0.969 ± 0.016; JVM13-cD1T286A, r = 
0.987 ± 0.007; Figure 5A). In accordance with the total RNA quan-
tification data, the cells overexpressing cyclin D1 showed lower 
gene expression levels than control cells at the 3 amounts of cells 
(P < 2.2 × 10–16; Figure 5A). Interestingly, all 36 genes expressed 
in control cells were downregulated in cyclin D1–overexpressing 
cells. To further confirm the global impact of cyclin D1 on mRNA 
Figure 6. Cyclin D1 colocalizes with RNA 
Pol II and promotes an increase in the Pol 
II pausing index. (A) Correlation between 
normalized cyclin D1 ChIP-Seq tag density in 
JVM13-cD1T286A and Pol II ChIP-Seq tag density 
at promoters in JVM13-ctrl and JVM13-D1T286A 
cells. Promoters were sorted into 50 equal-
sized groups based on ChIP-seq tag densities 
of cyclin D1. The x axis represents mean 
cyclin D1 normalized tags of the promoters in 
JVM13-cD1T286A cell lines. The y axis represents 
Pol II tag density in both cell lines. The linear 
regression line between cyclin D1 and Pol II 
presence in promoters is shown. (B) Average 
signal profiling of Pol II occupancy around the 
TSS (±3 kb) in JVM13-ctrl and JVM13-D1T286A 
inducible cell lines. The cyclin D1–binding 
profile in JVM13-cD1T286A cells is also shown. 
(C) Western blot showing different phos-
phorylated forms of Pol II in JVM13-ctrl, 
JVM13-D1T286A, and JVM13-D1 inducible cell 
lines. Gels were run in duplicate for the study 
of the phosphorylation forms. A representa-
tive Western blot (n = 3) for each antibody is 
presented. α-Tubulin of only one of the gels 
run in duplicate is shown as loading control. 
(D) Plot representing the pausing index. Lines 
illustrate rightward shift of pausing ratio at 
all genes with cyclin D1 in their promoter (–5 
kb, TSS) after cyclin D1 induction in JVM13-ctrl 
and JVM13-D1T286A cells. ***P < 2 × 10–16,  
Kolmogorov-Smirnov test. (E) Proportion of 
Pol II (IIo) and Pol (IIa) forms in primary MCL 
cases. P = 0.01, nonparametric Mann-Whit-
ney U test. (F) Pol II (8WG16) antibody signal 
in primary MCL cases. P = 0.03, nonparamet-
ric Mann-Whitney U test. (G) Coimmuno-
precipitation experiment in Z-138 cells using 
antibodies against cyclin D1 and control IgG. 
Immunoprecipitated proteins were analyzed 
by Western blot by blotting with cyclin D1 and 
Pol II antibody. Input at 1% was loaded as a 
control. (H) Coimmunoprecipitation experi-
ment in HEK-293T-CDK9-FLAG-D1T286A cells 
with anti-FLAG resins. Immunoprecipitated 
proteins were analyzed by Western blot by 
blotting with CDK9 and cyclin D1 antibodies. 
HEK-293T–D1T286A immunoprecipitation was 
used as negative control.
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Together, these results strongly suggest that the binding of cyclin 
D1 to gene promoters leads to a global transcription downmodula-
tion of expressed mRNAs also involving TSGs.
Cyclin D1 physically interacts with the transcription machinery 
and increases promoter-proximal Pol II pausing. To explore wheth-
er the cyclin D1–dependent transcriptome downmodulation was 
associated with changes in the RNA Pol II chromatin binding pro-
file, we performed Pol II ChIP-Seq experiments in control (JVM13) 
and cyclin D1–overexpressing cells (JVM13-D1T286A) (Supplemen-
analyzed in the cancer panel more frequently showed cyclin D1 
peaks at their promoters than the rest of the genes (81% vs. 61%, P 
= 0.038, Supplemental Figure 6A). Then we explored the binding 
of cyclin D1 to the promoters of the 583 TSGs in the MCL cell lines. 
We observed that a significantly greater fraction of TSGs showed 
cyclin D1 peaks in MCL cell lines (48% vs. 36%, P < 3.3 × 10–9, Sup-
plemental Figure 6B). Concordantly, the analysis of TSGs in pri-
mary MCL cases evidenced that this set of genes tends to show 
high expression levels in MCL cases (Supplemental Figure 6C). 
Figure 7. Cyclin D1 overexpression renders tumor cells sensitive to CDK9 inhibitors. (A) Cell survival of cyclin D1 inducible model after treatment with a 
CDK9 inhibitor (DBR) at increasing concentrations. JVM13-Ctrl and JVM13-D1T286A cells, after 24 hours of doxycylcine induction, were treated during 48 hours 
with DBR. Results are shown as mean ± SEM with respect to untreated cells (mean ± SEM, n = 3). *P < 0.05, Student’s t test. (B) MCL cell lines were treat-
ed during 72 hours with DBR. Results are shown with respect to untreated cells (mean ± SEM, n = 4). *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test. 
(C and D) Cell survival of MCL cell lines (C) and MM cell lines (D) after treatment with triptolide at 40 nM. Exponentially growing cell lines were treated, and 
cell survival was measured at 48 hours. Results are shown with respect to untreated (mean ± SEM, n = 4). *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t 
test (C) or mixed-effects models (D). (E and F) Cell survival of 9 primary MCL cases after treatment with 60 μM DBR (E) or 200 nM triptolide (F). Cell surviv-
al was measured at 72 hours after treatment. Survival was calculated with respect to untreated controls, and the means of duplicate experiments for each 
group are represented. Nonparametric Mann-Whitney U test was applied. Holm-Bonferroni correction for multiple comparisons was applied to A–C.
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a CTD modification associated with active elongation (Figure 6C). 
Concordantly, the 8WG16 antibody, which binds to unphosphory-
lated CTD and more weakly to Ser5-phosphorylated CTD, showed 
higher signal intensity in cyclin D1–overexpressing cells (Figure 6C 
and ref. 33). These Pol II forms are associated with paused poly-
merase or early elongation complexes. This Pol II phosphorylation 
pattern supports the view that cyclin D1 overexpression increas-
es promoter-proximal Pol II pausing. To confirm whether the Pol 
II pause release was affected by overexpression of cyclin D1, we 
established the pausing index by determining the ratio between Pol 
II occupancy at promoters and gene body regions (34). This analy-
sis showed that cyclin D1 overexpression led to an augmented Pol II 
pausing index (Figure 6D). Together, these results strongly support 
that the reduction of total nascent transcription following cyclin D1 
overexpression observed in lymphoid cells was due to increased 
promoter-proximal Pol II pausing.
To investigate whether the phosphorylation pattern of Pol II 
could be dysregulated in primary MCL cases, we analyzed the 
tal Figure 7A). Observing results concordant with the association 
between cyclin D1 chromatin binding and transcriptional levels, 
we found a strong correlation between the tag density of cyclin D1 
and Pol II together with a colocalization of both binding profiles 
around the TSS (Figure 6, A and B). Interestingly, JVM13-D1T286A 
cells showed higher Pol II loading at promoters, and this differ-
ence was more evident in highly expressed genes (Figure 6B and 
Supplemental Figure 7B). These results suggest that the observed 
transcriptome downmodulation was not due to reduced Pol II 
recruitment to promoters, but was related to increased promoter- 
proximal Pol II pausing. Consistent with this scenario, cyclin D1–
overexpressing cells displayed levels of Pol II protein similar to 
those in control cells (Figure 6C; Pol II [N-20]), indicating that the 
increased promoter occupancy by Pol II was not due to the pres-
ence of higher Pol II levels. Interestingly, the phosphorylation sta-
tus of the C-terminal domain (CTD) of Pol II was different in cyclin 
D1–expressing cells as compared with the control cells. Cyclin D1–
overexpressing cells showed lower levels of Ser2 phosphorylation, 
Figure 8. Proposed model for 
cyclin D1–dependent global 
transcriptional downregulation, 
a side effect of its oncogenic 
overexpression. (A) Cyclin D1 
canonical cell cycle role in normal 
cells. (B) Overexpression of cyclin 
D1, in addition to cell cycle induc-
tion, may interact with CDK9 and 
interfere with the normal release 
of paused Pol II, compromising 
active elongation. This would 
lead to a global transcription 
downmodulation, including of 
TSGs. The dotted lines indicate 
other potential oncogenic 
effects, such increased genomic 
instability due to augmented 
conflicts between transcription 
and DNA replication machinery.
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whether the sensitivity to transcription inhibitors was related to 
the cyclin D1 levels, we analyzed the response of MCL cell lines 
to DRB. The MCL cell lines showed a significant increase in apop-
tosis following DRB treatment (Figure 7B). Interestingly, the MCL 
cell lines with higher amounts of cyclin D1 and lower RNA content 
per cell showed greater sensitivity to DRB (Z-138 and UPN-1).
To further investigate the synthetic lethality interaction 
between cyclin D1 overexpression and transcription inhibition, 
we treated MCL and MM cell lines with triptolide, a transcription 
inhibitor that has been used for cancer treatment, with promising 
results (37). This inhibitor promotes the degradation of RPB1, the 
largest subunit of RNA Pol II (38). Again, UPN1 and Z-138 showed 
the greatest sensitivity to triptolide (Figure 7C). Interestingly, the 
cyclin D1–positive MM cell lines that showed a smaller amount of 
total RNA also displayed a significantly greater sensitivity to trip-
tolide than cyclin D1–negative MM cell lines (Figure 7D). These 
results suggest that high cyclin D1 expression leads to increased 
sensitivity to transcription inhibitors.
To test whether this synthetic lethality interaction could 
be observed in primary MCL cases, we treated cells from MCL 
patients with DRB and triptolide. We observed that primary MCL 
cells with higher levels of cyclin D1 were more sensitive to DRB 
and triptolide than MCL cells with smaller amounts of cyclin D1 
(Figure 7, E and F). Overall, these results suggest the existence of 
a potential synthetic lethality interaction between the overexpres-
sion of cyclin D1, responsible for a global transcription downmod-
ulation, and transcription inhibitors.
Discussion
We investigated whether the oncogenic overexpression of cyclin 
D1 is responsible for a transcriptional dysregulation in lymphoid 
tumor cells. As a model, we used MCL cells characterized by the 
constitutive overexpression of cyclin D1 due to the t(11;14) trans-
location. We found that endogenous cyclin D1 showed widespread 
binding to promoter regions of active genes, and its overexpres-
sion was responsible for a global transcriptional downmodulation 
in these malignant B cells. This dysregulation seems to be medi-
ated by the interference of the overexpressed cyclin D1 with the 
release of promoter-proximal paused Pol II. The interaction of 
overexpressed cyclin D1 with the transcription machinery and 
the consequent global RNA downmodulation rendered the tumor 
cells more sensitive to transcription inhibitors.
Our genomic analysis of cyclin D1–chromatin interaction 
revealed a high and somewhat unexpected number of cyclin D1 
binding sites that positively correlated with cyclin D1 protein 
levels and preferentially occurred at promoters close to the TSS. 
Analysis of the relationship between the cyclin D1 promoter occu-
pancy and chromatin states together with the transcriptional out-
put demonstrated that cyclin D1 binds globally to active promoters 
and these interactions are proportional to the mRNA abundance 
of targeted genes. Our results are in agreement with the observa-
tion that exogenous cyclin D1 targets promoters of genes highly 
expressed during retina development in cyclin D1–knockin mouse 
embryos (39). The density of cyclin D1 peaks in MCL cells was 
higher than that reported recently for exogenous cyclin D1 in 
mouse cancer cell lines and retinal tissue (39–41). This difference 
could be explained by the extremely high cyclin D1 protein levels 
expression of Pol II in a series of cases (n = 14). All samples showed 
expression of the CDT hyperphosphorylated form of Pol II (IIo), 
whereas expression of the hypophosphorylated CTD form (IIa) 
was heterogeneous among primary MCL cases (Supplemental 
Figure 7C). We established a ratio between the levels of the IIa and 
IIo forms and the amount of total Pol II. When we classified the 
primary MCL cases in 2 groups based on their low or high cyclin 
D1 protein levels (Supplemental Figure 7C), we observed that the 
proportion of the hyperphosphorylated Pol II (IIo) form was sig-
nificantly greater in MCL cases with low cyclin D1 levels (Figure 
6E), whereas the MCL cases with high cyclin D1 showed a signifi-
cantly greater proportion of the hypophosphorylated form (IIa) 
(Figure 6E). This association between the hypophosphorylated 
form of the Pol II and the levels of cyclin D1 was confirmed using 
the 8WG16 antibody (Figure 6F and Supplemental Figure 7C). 
Overall, these results suggest that the overexpression of cyclin D1 
may impact the transcription process by dysregulating RNA Pol II 
CDT phosphorylation.
We next explored whether the transcription dysregulation pro-
moted by cyclin D1 overexpression could be mediated by an interac-
tion of the cyclin with the transcription machinery. Cyclin D1 coim-
munoprecipitation analysis in MCL cell lines showed that indeed 
cyclin D1 interacts with Pol II (Figure 6G and Supplemental Figure 
8A). Furthermore, the association found between the amount of 
cyclin D1 and the hypophosphorylation pattern compatible with 
paused Pol II led us to investigate whether this phenotype could be 
mediated by an off-target effect of the overexpressed cyclin D1 on 
the cyclin-dependent kinase CDK9. This CDK is the kinase subunit 
of positive transcription elongation factor b (P-TEFb) required for 
release of paused Pol II and responsible of Ser2 phosphorylation 
during active elongation (35). In order to test whether cyclin D1 
interacts with CDK9, we transduced HEK-293T cells with cyclin 
D1 (D1T286A) and CDK9 (CDK9-Flag) and performed coimmuno-
precipitation experiments. Interestingly, we observed an interac-
tion between CDK9 and cyclin D1 proteins (Figure 6H). Moreover, 
endogenous coimmunoprecipitation experiments in MCL cell lines 
confirmed this cyclin D1–CDK9 interaction (Supplemental Figure 
8, B and C). These results suggest that cyclin D1 overexpression 
may dysregulate the release of paused Pol II through its binding to 
CDK9. Together, these results indicate that cyclin D1 overexpres-
sion determines a global transcriptome downmodulation by inter-
acting with the transcription machinery and interfering with the 
release of promoter-proximal paused Pol II.
Cyclin D1 overexpression sensitizes cells to transcription inhibi-
tors. The global transcriptional downmodulation caused by cyclin 
D1 overexpression led us to hypothesize that cyclin D1 overex-
pression could render cells more sensitive to drugs targeting the 
transcription machinery. To explore whether cyclin D1 overex-
pression sensitizes cells to transcription inhibitors, we treated 
control (JVM13) and cyclin D1–overexpressing (JVM13-D1T286A) 
cells with 5,6-dichloro-1-β-ribofuranosyl benzimidazole (DRB), a 
transcription inhibitor that causes premature chain termination, 
with CDK9 being its major target. We used DRB at 2 different con-
centrations (20 μM and 40 μM) below the levels reported to fully 
inhibit transcription (100 μM) (36). This experiment demonstrat-
ed significantly increased sensitivity to DRB in cyclin D1–overex-
pressing cells compared with control cells (Figure 7A). To explore 
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cyclin D1 could sequester CDK9 in inactive complexes, compro-
mising the CDK9-dependent Ser2 phosphorylation required for 
active elongation. This would give rise to the accumulation of 
paused RNA Pol II and the global transcriptional downmodulation 
we identified (Figure 8). Further analyses should clarify in more 
detail how cyclin D1 interferes with the activation of the transcrip-
tion machinery, whether other CDK9 functions are compromised, 
and whether off-target effects may be a common phenomenon fol-
lowing the pathogenic overexpression of other cyclins.
The increased sensitivity to a CDK9 inhibitor displayed by 
lymphoid cells following cyclin D1 overexpression together with 
the significantly greater sensitivity to transcription inhibitors 
observed in MCL and MM cell lines and in primary MCL cases with 
higher cyclin D1 levels suggests the existence of a synthetic lethal-
ity between cyclin D1 overexpression and transcription inhibition. 
This lethal interaction opens opportunities for new treatment strat-
egies in cyclin D1–overexpressing tumors. In this sense, a recent 
study has reported that SNS-032, a CDK7/9 inhibitor, induces 
cytotoxicity in MCL cells (51). Interestingly, consistent with our 
results, the SP-53 MCL cell line, which displays very low levels of 
cyclin D1 (52), was the cell line least sensitive to SNS-032 (51).
The identification of a cyclin D1–dependent global transcrip-
tional downmodulation may seem at first glance inconsistent with 
a potential oncogenic effect of cyclin D1 in MCL, and raises the 
question about its potential significance. We may hypothesize that 
this transcriptional downmodulation could be a mechanism that 
participates in the transcriptional shutdown during the S phase fol-
lowing the G1/S transcriptional wave or during M-phase in a nor-
mal cell cycle (53, 54). This dysregulation also could correspond to 
a nonphysiological collateral effect produced by the very high lev-
els of cyclin D1. Further studies should clarify whether this down-
modulation responds to a physiological role of cyclin D1.
The hypothesis that the transcriptional downregulation medi-
ated by high levels of cyclin D1 plays a potential oncogenic role 
in MCL is suggested by the fact that MCL cells accumulate other 
genetic alterations, in addition to the t(11;14)(q13;q32) transloca-
tion, that lead to increased cyclin D1 levels, emphasizing that cyclin 
D1–dependent phenotypes might be important in MCL pathogene-
sis. Interestingly, the presence of more stable cyclin D1 transcripts 
and higher protein levels correlates with increased aggressiveness 
of the tumors (22). Although this aspect requires further study, we 
may speculate that a reduction of the transcriptome program of 
a cell could have an oncogenic impact by decreasing the levels of 
active TSGs, including cell cycle checkpoint genes, which are fre-
quently inactivated or downregulated during oncogenesis (Figure 
8). Also, we may hypothesize that the accumulation of paused Pol 
II due to cyclin D1 overexpression might facilitate the generation 
of genomic instability by increasing the probability of conflicts 
between DNA replication and transcription machineries. The col-
lision between these machineries may cause an increase in DNA 
breaks as a consequence of replication fork stalling and collapse 
leading to recombination and chromosome rearrangements (Fig-
ure 8 and ref. 55). In this sense, it has been recently shown that arti-
ficially stabilized transcription initiation complexes can impede 
replication fork progression (56). Further studies should clarify the 
potential conflicts between promoter-proximal paused Pol II medi-
ated by cyclin D1 overexpression and DNA replication forks.
present in MCL cell lines. Furthermore, we observed that exoge-
nous cyclin D1 was recruited to promoters that are preconfigured 
in an active state in the absence of cyclin D1, and the recruitment 
seems to be proportional to the expression levels of the target-
ed genes. This chromatin behavior was strikingly similar to that 
reported for MYC in human tumor cells and mouse primary lym-
phocytes (26–28, 42). Recent studies have associated the MYC 
chromatin-binding profile with its capacity to globally enhance 
transcription at all active loci, giving rise to the model of MYC as a 
global transcriptional amplifier (26, 27).
Surprisingly, despite the substantial similarities between the 
chromatin-binding behavior of cyclin D1 and MYC, the overex-
pression of cyclin D1 in lymphoid cells was responsible for a sig-
nificant reduction in cell RNA content that was proportional to 
cyclin D1 protein levels, an effect that was cell cycle independent 
and was related to a reduced transcription rate. The analysis of 
MCL and MM cell lines and primary MCL cases confirmed the 
negative correlation between cyclin D1 protein levels and total 
RNA cell content. Moreover, the digital quantification of 2 inde-
pendent gene sets showed that cyclin D1 overexpression also 
determined a downregulation of most expressed mRNA tran-
scripts. These results suggest that the widely spread binding of 
cyclin D1 to promoters decreases the nascent transcription of 
bound genes, producing a significant reduction in cellular mRNA 
content. Thus, cyclin D1 seems to act as global transcriptome reg-
ulator, decreasing the overall gene transcription program of the 
cells. As far as we know, this is the first time that a global tran-
scription downregulation effect has been reported for a protein 
outside the basal transcription machinery.
The phosphorylation state of the CTD of Pol II is critical in deter-
mining its activity during the transcription process (43, 44). Initial-
ly, Pol II is recruited into the pre-initiation complex with a hypo-
phosphorylated CTD (IIa), and later, during initiation, the CTD is 
phosphorylated on Ser5 mainly by CDK7 and on Ser2 during active 
elongation by CDK9, the kinase component of P-TEFb, resulting 
in Pol II hyperphosphorylation (IIo). We observed that the over-
expression of cyclin D1 determined a shift in the phosphorylation 
pattern of the Pol II CTD from a productive elongation to a paused 
polymerase pattern (35). Moreover, primary MCL cases with high-
er levels of cyclin D1 showed an increased proportion of hypophos-
phorylated forms of Pol II (IIa). These phosphorylation patterns 
were consistent with the observed accumulation in promoter- 
proximal regions of paused Pol II following cyclin D1 overex-
pression. Conversely, the global MYC-dependent transcription 
amplification was related to the capacity of MYC to increase Pol 
II processivity at all transcribed genes (26, 27, 45, 46). In light of 
these results, we postulated that the phosphorylation pattern shift 
and the global transcriptional downmodulation we observed could 
be mediated by the physical interaction of cyclin D1 with the tran-
scription machinery. This scenario is supported by the coimmu-
noprecipitation of cyclin D1 with RNA Pol II and CDK9 observed 
in MCL cell lines and in HEK-293T cells. Previous studies have 
reported the interaction of cyclin D1 with CDKs besides the canon-
ical CDK4/6 in different cell models, including CDK1, CDK2, 
CDK3, CDK5, and CDK11 (39, 47–49). Furthermore, the binding 
of cyclin D1 to noncanonical CDK partners has been described 
to inhibit the targeted CDK (50). In a similar way, the binding of 
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the presence of doxycycline (0.1 μg/ml) were treated with DRB (Sigma- 
Aldrich) or triptolide (Selleck Chemicals) at the indicated final con-
centrations. The annexin-positive fraction was determined by cell 
cytometry 48 hours after DRB treatment or 72 hours after triptolide 
treatment using an Annexin V Apoptosis Detection Kit FITC (eBiosci-
ence) according to the manufacturer’s guidelines. Nine MCL primary 
samples were treated for 72 hours with DRB or triptolide at the indicat-
ed concentrations, and apoptosis was analyzed in the CD19-positive 
fraction (CD19-PE, Becton Dikinson) using the Annexin V Apoptosis 
Detection Kit FITC.
ChIP. For cyclin D1, crosslinked chromatin was fragmented with 
a Covaris S220 instrument using the truChIP HighCell Chromatin 
Shearing Kit with Non-ionic Shearing Buffer. Immunoprecipitation 
was performed with anti–cyclin D1 antibody or control IgG. Chroma-
tin was de-crosslinked and purified with Agencourt AMPure beads 
(Beckman Coulter) according to the manufacturer’s guidelines. 1% 
of sheared DNA was used as input control for qPCR validation and 
for analyzing sonication efficiency. Equal volumes of eluted chipped 
DNA were amplified using SYBR Green PCR Master Mix (Applied Bio-
systems) under the manufacturer’s guidelines. Specific primers were 
designed for the peaks obtained in the ChIP-Seq analysis (Supplemen-
tal Table 3). Primers for negative regions were also designed to test the 
specificity of the enrichment. For Pol II, crosslinked chromatin was 
sonicated with a Bioruptor (Diagenode). Shared chromatin was immu-
noprecipitated using anti–Pol II antibody, or control IgG chromatin 
was decrosslinked and purified using the phenol-chloroform method. 
1% of sheared DNA was used as input control for qPCR validation and 
for analyzing sonication efficiency.
ChIP-Seq and RNA-Seq. Library preparation for ChIP-Seq was per-
formed using the NEBNext Ultra DNA Library Prep Kit (New England 
BioLabs). Briefly, the immunoprecipitated DNA (10 ng) was end- 
repaired, and A-nucleotide overhangs were then added, followed by 
adapter ligation, PCR enrichment (15 cycles), and purification with 
AMPure beads (ratio, 1.25) (Beckman Coulter). The purified DNA 
library products were evaluated and quantified using Bioanalyzer (Agi-
lent, High Sensitivity DNA Kit) and the KAPA Library Quantification 
Kit (Kapa Biosystems), respectively. Sequencing was performed on the 
Illumina MiSeq instrument using the 50-cycles V2 kit. For RNA-Seq, 
total RNA was isolated using TRIzol (Zymo Research). Preparation 
of RNA-Seq libraries was carried out using the TruSeq RNA Sample 
Preparation Kit (Illumina) according to the manufacturer’s standard 
protocol. The libraries were 75-bp paired-end sequenced at approx-
imately 80 million reads per library with Illumina technology. RNA-
Seq data were deposited in the NCBI’s Gene Expression Omnibus 
database (GEO GSE118301)
RNA extraction and quantification by flow cytometry. Cells were 
counted in duplicate from cell cultures using FACS (Attune NxT, 
Thermo Fisher Scientific). Total RNA was extracted from 1 million 
cells using an RNeasy Mini Kit (QIAGEN) under the manufacturer’s 
guidelines. RNA extracts were quantified by Nanodrop ND-1000 
(Thermo Fisher Scientific). Cell pellets of 1 million cells were fixed in 
0.5% formaldehyde for 15 minutes on ice. Cells were pelleted, washed 
with cold PBS, and resuspended in 300 μl cold PBS. Then 700 μl of 
100% cold ethanol was added dropwise during vortexing. The cells 
were incubated overnight at –20°C. Cell pellets were washed once with 
PBS at room temperature and resuspended in 250 ml HBSS medium 
with calcium and magnesium. This suspension was incubated with a 
In conclusion, we have identified that oncogenic cyclin D1 
overexpression produces a global transcriptome downmodula-
tion. This dysregulation might, at least in part, be mediated by the 
interaction of cyclin D1 with transcription machinery that would 
compromise the release of promoter-proximal paused Pol II. This 
global transcriptional downmodulation induced by cyclin D1 over-
expression seems to generate a synthetic lethality interaction that 
could be exploited therapeutically.
Methods
Further information can be found in Supplemental Methods, available 
online with this article.
Cell lines and primary MCL cells. For this study, we used 5 well- 
characterized MCL cell lines (Z-138, GRANTA-519, JeKo-1, UPN-1, 
and JVM-2) (24), 7 MM cell lines (JJN-3, RPMI 8226, NCI-H929, 
U266, KMS-12-PE, KMM-1, and ARP-1; purchased from the German 
Collection of Microorganisms and Cell Cultures and ATCC), a lym-
phoblastoid leukemic cell line (JVM-13; ATCC CRL3003), and HEK-
293T cells (ATCC CRL-3216). Cells were cultured at 37°C and 5% 
CO2 in RPMI (Gibco), except for GRANTA-519 and HEK-293T cells in 
DMEM (Gibco). Media was supplemented with 10% FBS, 500 μg/ml 
streptomycin, and 500 U/ml penicillin (Gibco).
Primary MCL samples (>80% tumor cells) were obtained from 
peripheral blood samples of 14 MCL patients diagnosed according to 
WHO criteria. Tumor cells were isolated by centrifugation on a Ficoll-
Hypaque (GE Healthcare) gradient, cryopreserved, and maintained in 
the Hematopathology collection registered at the Biobank of Hospital 
Clínic – IDIBAPS (R121004-094).
Plasmids and infection procedures. Plasmids for constitutive infec-
tion used the backbone pBABE-puro retroviral vector. pBABE-puro 
was a gift from Hartmut Land, Jay Morgenstern, and Bob Weinberg 
(Addgene, plasmid 1764) (57). pBABE-puro-cyclinD1 (tagged with the 
27-base pair sequence HA) was a gift from William Hahn (Addgene, 
plasmid 9050). pBABE-Flag-Cdk9-IRES-eGFP was a gift from Andrew 
Rice (Addgene plasmid 28096) (58). Mutation T286A in the cyclin D1 
gene was inserted under the manufacturer’s guidelines using a Quik-
Change II Site-Directed Mutagenesis Kit (Agilent). All constructs were 
validated by sequencing. For cyclin D1 knockdown, we used MISSION 
pLKO.1-puro plasmids (Sigma-Aldrich) (Supplemental Table 4).
Constitutive overexpression models were achieved by spin- 
infection of JVM-13 or HEK-293T exponentially growing cells (1,350 g, 
90 minutes, 27°C) in the presence of Polybrene (Sigma-Aldrich) and 
supernatants containing viral particles produced in HEK-293T cells. 
HEK-293T CDK9-FLAG-GFP–infected cells were sorted by cell 
cytometry (BD LSRFortessa, BD Biosciences). Cyclin D1 constitutive 
models were selected after 1 week of puromycin treatment at 0.4 μg/
ml (Sigma-Aldrich). The inducible cell lines JVM-2 and JVM-13 were 
developed under the manufacturer’s guidelines using the plasmids 
of the Retro-X Tet-On Advanced Inducible Expression kit (Clon-
tech Laboratories). Silencing of cyclin D1 in exponentially growing 
GRANTA-519 cells was performed by lentiviral spin infection (1,000 
g, 90 minutes, 32°C) in the presence of Polybrene, followed by an 
additional 3 hours of incubation; the protocol was repeated for 2 con-
secutive days. Cells were selected with 0.5 μg/ml puromycin (Sigma- 
Aldrich) 24 hours after infection.
In vitro transcription inhibition experiments. Exponentially growing 
MCL cell lines and cyclin D1 inducible cells incubated for 24 hours in 
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used to define the functional pathways associated with cyclin D1–
bound genes. We performed hierarchical cluster analysis using 2 data-
bases (GOTERM_BP_FAT and KEGG_PATHWAY) and the EASE score 
(modified Fisher’s exact P value). The enrichment score was calculat-
ed as the geometric mean of –log EASE score, and the percentage of 
enrichment was calculated as described previously (40), based on the 
enrichment score of the top hits (enrichment score >5).
Affymetrix Expression Console software was used to compute 
robust multichip average (RMA) expression values from 122 MCL 
patients investigated with Affymetrix Human Genome U133 Plus 
2.0 gene expression arrays (Thermo Fisher Scientific) previously 
deposited in the NCBI’s Gene Expression Omnibus database (GEO 
GSE93291). For each gene, the probe set with the highest average 
signal was selected for the different analysis. RNA-Seq reads were 
aligned using Bowtie as described above. To quantify the expression 
of each gene, we used TopHat v2.0.9 (https://ccb.jhu.edu/software/
tophat) with default parameters and the human GRCh37/Hhg19 as a 
reference genome. Gene expression values (quantified as reads per 
kilobase of transcript per million reads [RPKMs]) were calculated 
using the edgeR Bioconductor package. Analysis of transcription fac-
tor binding sites was obtained using ChIP-Seq data from the ENCODE 
Project in GM12878 (https://www.encodeproject.org/), and data are 
available through the UCSC Genome Browser.
Statistics. Statistics and graphical results were done in R statisti-
cal computing language (v3.1.3) and GraphPad Prism version 4.00 for 
Windows (GraphPad Software). Data are mainly presented as mean 
± SEM. Differences in mean were analyzed using parametric (paired 
and unpaired Student’s t test and ANOVA) and nonparametric tests 
(Mann-Whitney, Kolmogorov-Smirnov, and χ2 tests). Correlations 
were evaluated by calculating Pearson’s or Spearman’s correlation 
coefficient or mixed-effects models among replicate measures, when 
appropriate. Multiple testing was performed by the Holm-Bonferroni 
method. Two-sided tests were applied throughout, and a P value less 
than 0.05 (after multiple-testing if required) was considered signifi-
cant. Statistical tests used are indicated in the figure legends.
Study approval. The study was approved by the Healthcare Eth-
ics Committee of the Hospital Clinic of Barcelona. Written informed 
consent was obtained from all participants, and the ethics committees 
approved this consent procedure in accordance with the principles of the 
Declaration of Helsinki.
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